Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial—A Retrospective Study on 10 Years of Practice

Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial—A Retrospective Study on 10 Years of Practice

(1) Background: Citrate is preferred in continuous renal replacement therapy (CRRT) for critically ill patients because it prolongs filter life and reduces bleeding risks compared to unfractionated heparin (UFH). However, regional citrate anticoagulation (RCA) can lead to acid–base disturbances, cit...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Rita Jacobs, Walter Verbrugghe, Jason Bouziotis, Ingrid Baar, Karolien Dams, Annick De Weerdt, Philippe G. Jorens
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2024-10-01
Saila:Life
Gaiak:
citrate anticoagulation
heparin
renal replacement therapy
filter lifespan
bleeding
acid–base disturbances
Sarrera elektronikoa:https://www.mdpi.com/2075-1729/14/10/1304

Internet

https://www.mdpi.com/2075-1729/14/10/1304

Antzeko izenburuak